Thiogenesis Therapeutics, Corp.
TTI.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.22M | 1.08M | 1.00M | 985.80K | 850.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.00M | 3.76M | 2.97M | 2.60M | 3.23M |
| Operating Income | -5.00M | -3.76M | -2.97M | -2.60M | -3.23M |
| Income Before Tax | -4.89M | -3.64M | -2.75M | -2.29M | -3.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.89 | -3.64 | -2.75 | -2.29 | -3.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.89M | -3.64M | -2.75M | -2.29M | -3.01M |
| EBIT | -5.00M | -3.76M | -2.97M | -2.60M | -3.23M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.10 | -0.08 | -0.06 | -0.05 | -0.07 |
| Normalized Basic EPS | -0.06 | -0.05 | -0.04 | -0.03 | -0.04 |
| EPS Diluted | -0.10 | -0.08 | -0.06 | -0.05 | -0.07 |
| Normalized Diluted EPS | -0.06 | -0.05 | -0.04 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 188.18M | 183.59M | 182.78M | 181.44M | 175.62M |
| Average Diluted Shares Outstanding | 188.18M | 183.59M | 182.78M | 181.44M | 175.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |